Kiniksa Pharmaceuticals Faces Capital Raising Hurdles Amid Stricter UK Shareholder Voting Laws
TipRanksApr 27 02:00 ET
Analyst Estimates: Here's What Brokers Think Of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) After Its First-Quarter Report
Yahoo FinanceApr 26 06:37 ET
Kiniksa Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group
Kiniksa Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group
Dow JonesApr 24 13:50 ET
Kiniksa Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/24/2024 63.49% Evercore ISI Group $25 → $30 Maintains Outperform 01/02/2024 36.24% Wedbush $23 → $25 Ma
BenzingaApr 24 13:38 ET
Express News | Kiniksa Pharmaceuticals Ltd : Evercore ISI Raises Target Price to $30 From $25
Moomoo 24/7Apr 24 09:18 ET
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q1 2024 Earnings Call Transcript
Yahoo FinanceApr 24 09:00 ET
Buy Rating Affirmed for Kiniksa Pharmaceuticals Amid Strong Q1 Performance and Promising Drug Prospects
TipRanksApr 24 05:44 ET
Earnings Call Summary | Kiniksa Pharmaceuticals(KNSA.US) Q1 2024 Earnings Conference
The following is a summary of the Kiniksa Pharmaceuticals Ltd. (KNSA) Q1 2024 Earnings Call Transcript:Financial Performance:Kiniksa Pharmaceuticals reported strong Q1 2024 results with an 85% year-ov
moomoo AIApr 23 16:12 ET · Conference Call
Buy Rating Affirmed for Kiniksa Pharmaceuticals Amidst Growth Potential and Strong Commercial Execution
TipRanksApr 23 11:05 ET
Kiniksa Pharmaceuticals Ltd (KNSA) Q1 2024 Earnings Overview: Surpasses Revenue Forecasts
Yahoo FinanceApr 23 08:53 ET
Express News | Kiniksa Expects 2024 Arcalyst Net Product Revenue Of $370M-$390M Compared To Prior Guidance Of $360M-$380M
Moomoo 24/7Apr 23 07:33 ET
Earnings Flash (KNSA) KINIKSA PHARMACEUTICALS Posts Q1 Revenue $79.9M, Vs. Street Est of $78.5M
07:32 AM EDT, 04/23/2024 (MT Newswires) -- Earnings Flash (KNSA) KINIKSA PHARMACEUTICALS Posts Q1 Revenue $79.9M, vs. Street Est of $78.5M
MT NewswiresApr 23 07:32 ET
Express News | Kiniksa Pharmaceuticals Ltd - Arcalyst 2024 Expected Net Product Revenue Increased to $370 - $390 Mln
Moomoo 24/7Apr 23 07:30 ET
Express News | Kiniksa Pharmaceuticals Ltd - Current Operating Plan Expected to Remain Cash Flow Positive on an Annual Basis
Moomoo 24/7Apr 23 07:30 ET
Express News | Kiniksa Pharmaceuticals Q1 Net Income USD -17.704 Million
Moomoo 24/7Apr 23 07:30 ET
Express News | Kiniksa Pharmaceuticals Q1 Operating Expenses USD 96.4 Million
Moomoo 24/7Apr 23 07:30 ET
Express News | Kiniksa Pharmaceuticals Q1 Product Revenue USD 78.885 Million
Moomoo 24/7Apr 23 07:30 ET
Kiniksa Pharmaceuticals 1Q Loss/Shr 25c >KNSA
Kiniksa Pharmaceuticals 1Q Loss/Shr 25c >KNSA
Dow JonesApr 23 07:30 ET
Express News | Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution
Moomoo 24/7Apr 23 07:30 ET
Express News | Kiniksa Pharmaceuticals Q1 EPS USD -0.25
Moomoo 24/7Apr 23 07:30 ET
No Data
No Data